Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Plasticell and EMD Millipore Complete Licensing Deal

Published: Tuesday, January 01, 2013
Last Updated: Tuesday, January 01, 2013
Bookmark and Share
Deal to distribute fully defined, xeno-free mesenchymal stem cell differentiation media.

Plasticell has licensed EMD Millipore to distribute a superior, single-application osteogenic medium discovered using the award winning, massively parallel combinatorial screening system, CombiCult®.

The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations.

Under the terms of the contract, EMD Millipore has secured a license to distribute the medium globally for research purposes with Plasticell retaining full rights over therapeutic applications.

Early adopters of the medium include Organovo, Inc., a leading San Diego biotech company developing tissue bioprinting applications.

Dr. Eric Michael David MD JD, Chief Strategy Officer of Organovo, Inc. commented, “Organovo, Inc considers Plasticell's CombiCult® bone differentiation media to be a significant leap forward in helping to create 3D bone tissue for a multiple variety of research and transplant applications. Brief incubation of 3D tissue constructs generated with Organovo's NovoGen MMX Bioprinter™ in Plasticell's CombiCult® bone differentiation media produces tissue of impressive osteogenic potential, including key bone-specific and mineralization markers. We found we could rapidly fabricate functional, fully human tissue derived from MSCs and the ECM proteins they produce. Plasticell's media enabled a remarkable efficiency in tissue fabrication and maturation, and we look forward to continuing to work with Plasticell's technology to generate additional bioprinted 3D tissues from well-characterized, renewable, quality cell sources such as MSCs.”

The optimized osteogenic medium was developed using CombiCult® to perform a rapid screen of 3,375 combinations of fully defined cell culture media, equivalent to hundreds of thousands of combinations of media components.

“The formulation of this medium in under 3 months from start to finish is a clear demonstration of the capability of the CombiCult® technology to deliver market-leading products in record time,” said Dr Jey Jeyakumar, the Principal Scientist who performed the factor screen and optimized the media formulation.

In contrast to all currently available osteogenic media, Plasticell’s formulation is fully defined (serum-free) and contains no xenogeneic components.

Moreover, mineralization can be detected in less than one week, whereas competing products that contain serum require approximately 21 days to attain similar levels of bone formation.

Plasticell’s unique medium will be available for research purposes from EMD Millipore in Q3 2012 and available now for commercial applications directly from Plasticell.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Plasticell Completes £1.32 Million Financing to Advance Therapeutic Projects
Plasticell announces the completion of a two-part equity financing round, raising a total of £1.32 million from its shareholders and new investors.
Friday, November 04, 2016
Plasticell, CellSpring Collaborate
Collaboration aims to validate osteogenic cell therapy and 3D cell culture models for high performance drug screening.
Monday, September 19, 2016
Plasticell, NUI Galway Collaborate
Plasticell has announced the signing of a collaboration agreement with the National University of Ireland, Galway focused on methods of eradicating cancer stem cells.
Tuesday, August 02, 2016
Plasticell Awarded the Queen’s Award for Enterprise in Innovation 2016
Plasticell is pleased to announce it has been awarded the 2016 Queen’s Award for Enterprise in Innovation.
Monday, April 25, 2016
Plasticell and Pierre Fabre Laboratories Sign a Partnership
Company has announced collaboration to identify natural stimulants of brown fat for treatment and prevention of obesity and diabetes.
Wednesday, February 24, 2016
Plasticell Appoints Dr Aaron T. T. Chuang as Chief Scientific Officer
New appointment further strengthens the company’s expertise in regenerative medicine product development.
Tuesday, June 16, 2015
Plasticell Wins Innovate UK Funding
Funding for £1.6 million cord blood stem cell manufacturing project.
Friday, February 06, 2015
Plasticell Signs Deal with JCR Pharmaceuticals
Collaboration agreement to use CombiCult® stem cell technology in Japan.
Tuesday, February 25, 2014
Additional Family of CombiCult® Patents Granted in USA, Europe, Australia and Singapore
Newly granted patents cover the use of nanomaterial tags.
Tuesday, November 19, 2013
Plasticell and Veritas Announce an Exclusive Distribution Agreement in Japan
Veritas engaged as exclusive distributor for Plasticell’s services and products, including CombiCult®.
Monday, June 18, 2012
Plasticell Announces Grant of Fundamental CombiCult™ Patents in USA and Japan
Patents have now been issued in Europe, USA, Japan, Australia and Singapore.
Tuesday, February 14, 2012
Plasticell Wins Further Funding for Stem Cell Manufacturing Project
Technology Strategy Board will provide a grant of approximately £750k towards a £1.5m project.
Wednesday, December 14, 2011
Plasticell Delivers Differentiation Protocols to Stemnion, Inc.
Plasticell announces successful completion of a collaboration with Stemnion, Inc..
Tuesday, August 09, 2011
Plasticell Spins Out Regenerative Drug Discovery Venture
New demerged business called ‘Progenitor Labs’.
Thursday, April 14, 2011
Plasticell Completes £3.5 Million Financing Round
Capital injection to expand business development and marketing initiatives to increase growing customer base.
Wednesday, February 16, 2011
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Forensic 3D Documentation of Skin Injuries
In this study, the validity of using photogrammetry for documenting injuries in a pathological context was demonstrated.
3-D Printed Dog’s Nose Improves Vapor Detection
By mimicking how dogs get their whiffs, a team of government and university researchers have demonstrated that “active sniffing” can improve by more than 10 times the performance of current technologies that rely on continuous suction to detect trace amounts of explosives and other contraband.
New Markers for Forensic Body-fluid Identification
University of Bonn researchers have successfully identified specific Micro-RNA signatures to help forensically identify body fluids.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!